Actively Recruiting

Phase Not Applicable
Age: 40Years - 80Years
All Genders
NCT07513415

A Comparative Study on the Safety and Efficacy of the Intra-Articular Injectable Filler ALLOHEAL in Patients With Knee Osteoarthritis

Led by Endovision Co., Ltd. · Updated on 2026-04-07

286

Participants Needed

1

Research Sites

147 weeks

Total Duration

On this page

Sponsors

E

Endovision Co., Ltd.

Lead Sponsor

T

The Catholic University of Korea, Uijeongbu St. Mary's Hospital

Collaborating Sponsor

AI-Summary

What this Trial Is About

ENDOVISION Co., Ltd. has developed an intra-articular knee injection with sodium polynucleotide, chitosan, and type I collagen as its main components, and aims to demonstrate the non-inferiority of the investigational device, ALLOHEAL, compared with the control device, Conjuran®, when administered intra-articularly to patients with knee osteoarthritis for the purpose of reducing mechanical friction within the joint cavity.

CONDITIONS

Official Title

A Comparative Study on the Safety and Efficacy of the Intra-Articular Injectable Filler ALLOHEAL in Patients With Knee Osteoarthritis

Who Can Participate

Age: 40Years - 80Years
All Genders

Eligibility Criteria

Eligible

You may qualify if you...

  • Men and women aged 40 to less than 80 years at the time of consent
  • Diagnosed with knee osteoarthritis per American College of Rheumatology guidelines within 24 weeks before or at screening
  • Pain in the osteoarthritic knee for at least 8 weeks
  • Kellgren-Lawrence grade I-III severity in the target knee based on X-ray at screening
  • Weight-bearing Visual Analog Scale score of at least 40 mm in the target knee at screening
  • Body Mass Index (BMI) below 35 kg/m² at screening
  • Able to walk without assistive devices or have used the same device consistently for at least 24 weeks prior
  • Willing to sign informed consent
  • Able to understand and follow study procedures and visit schedule
Not Eligible

You will not qualify if you...

  • History of surgery or arthroscopic treatment on the target knee within 24 weeks before screening
  • Need for surgical intervention on the target knee at screening
  • Ligament instability grade II or higher in the target knee at screening
  • Orthopedic issues like fractures or joint deformities affecting the target knee
  • Pain from other joint problems or osteoarthritis in different areas that affect knee pain assessment
  • Certain comorbidities including rheumatoid arthritis, gout, severe liver, heart, or kidney disease, recent malignancy, and coagulation disorders
  • Infection, inflammation, or severe fluid buildup in the target knee
  • Local skin disorders at the target knee
  • Hypersensitivity to porcine-derived products or components of the investigational device

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Trial Site Locations

Total: 1 location

1

Seok Jung Kim

Uijeongbu-si, South Korea

Actively Recruiting

Loading map...

Research Team

K

Kim

CONTACT

How is the study designed?

Study Type

INTERVENTIONAL

Masking

DOUBLE

Allocation

RANDOMIZED

Model

PARALLEL

Primary Purpose

TREATMENT

Number of Arms

2

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here